Moraine police offering safety program for seniors, others
MORAINE, Ohio (WDTN) — A program offering additional safety checks to seniors and individuals with disabilities is open in Moraine.
The Moraine Police Department is reminding the community it offers a service for certain residents to have extra safety measures.
According to the department, residents who are at least 65 years old with 'serious medical conditions' and live alone, and individuals with Alzheimer's, Autism, Dementia or developmental disorders are among those who can participate.
'Through MSSI, our Police and Fire Departments can quickly access critical information using secure databases, ID bracelets, and lock boxes — ensuring help gets where it's needed fast,' said MPD.
Moraine police said the program is voluntary. To enroll in the program, call Moraine Police Department at 937-535-1166, ask for Sergeant Dyer and reference the program.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 hours ago
- Medscape
Up to 44% of Dementia Cases Preventable
Maintaining optimal vascular health throughout late life can significantly lower the risk of developing dementia before age 80 years, new research showed. Investigators estimated the proportion of new dementia cases linked to modifiable vascular risk factors. The results suggested that 22%-44% of dementia cases by age 80 years could be attributed to poor vascular health through age 74 years. The findings highlighted the 'potentially immense value of early detection of vascular risk factors and primordial prevention (eg, vis-à-vis promotion of physical activity and healthy body weight management) beginning in midlife,' wrote the study team, led by Jason Smith, PhD, with Johns Hopkins Bloomberg School of Public Health in Baltimore. The study was published online on June 2 in JAMA Neurology . Vascular Health Equals Brain Health Hypertension, diabetes, and smoking are widely recognized modifiable vascular risk factors for dementia. While their roles have been studied individually, the cumulative impact of these risk factors across the lifespan — and how this varies by genetic background, race, and sex — has been less clear. Smith and colleagues used data from the Atherosclerosis Risk in Communities Neurocognitive Study, with 33 years of follow-up, to assess the fraction of dementia attributable to hypertension, diabetes, and smoking measured at different life stages. A total of 7731 participants were included in the analysis of risk factors measured at age 45-54 years (58% women, 71% White, 29% Black); 12,274 contributed data at age 55-64 years (55% women, 76% White, 24% Black); and 6787 contributed data at age 65-74 years (56% women, 80% White, 20% Black). Overall, a total of 2218 people developed dementia by their 80th birthday. By age 80 years, the population attributable fraction of dementia attributable to at least one vascular risk factor measured at age 45-54 years was 22%; at 55-64 years, it was 26%, and at 65-74 years, it was 44%. Only 2%-8% of dementia cases occurring after age 80 years were attributable to these vascular risk factors. Subgroup differences emerged. For example, the attributable fractions for the vascular risk factors were higher in APOE-ε4 noncarriers aged 55 years or older (range, 33%-61%). 'This reflects the fact that in populations with lower genetic Alzheimer risk, the extent of the relative contribution of vascular disease to dementia risk is greater,' the study team explained. Attributable fractions for the vascular risk factors were also higher in Black individuals aged 45 years or older (range, 26%-53%) and women aged 55 years or older (range, 29%-51%). Risk factor clusters such as hypertension plus diabetes and smoking plus diabetes significantly increased dementia risk, with hazard ratios ranging from 2.00 to 3.54, depending on age and risk factor combination. The importance of hypertension and diabetes increased with age, whereas the importance of smoking decreased with age. 'Given the contribution of vascular disease to dementia and the overlap in risk factors between CVD and dementia, interventions that address these underlying risk factors have the potential to reduce the risk of both outcomes,' the co-authors of a linked editorial said. These results also suggest that 'to be optimally effective, interventions to reduce dementia risk by addressing vascular risk factors may need to be individualized and targeted based on factors such as age, genetics, race, and sex,' Roch A. Nianogo, MD, PhD, with University of California, Los Angeles, and Deborah E. Barnes, PhD, MPH, with University of California, San Francisco, wrote.
Forbes
3 hours ago
- Forbes
Funding women's health innovations is a massive economic opportunity.
Women's health now includes conditions that affect them exclusively, differently and ... More disproportionately. That includes everything from endometriosis and menopause to heart disease and Alzheimer's. Unprecedented advances in medical science mean women live longer, yet they die in poorer health than men. The reasons are structural and systemic. The health system continues to be shaped by outdated definitions, insufficient research, and lopsided funding, according to the recently released Accenture and Springboard Enterprises' 2025 State of Women's Health report. What is needed now is not just more lip service, but a realignment of investment priorities—private, public, and philanthropic—that recognizes the full spectrum of women's health. 'Women's health is still vastly misunderstood,' says Alice Zheng, MD, MBA, and a partner at Foreground Capital, a venture fund focused on women's health. 'There's opportunity in almost every place you look.' NIH funding and VC investments In 2024, healthtech startups raised $28.5 billion in venture capital. Of that, just $1.6 billion went to femtech, products and services focused on women's health. That's about 6% of the pie. Meanwhile, of the $43.7 billion in research grants distributed by the National Institutes of Health (NIH) in 2023, only $3.5 billion—8%—was directed toward women's health. These gaps persist despite women comprising more than half of the U.S. population and 51% of medical school graduates. 'It all starts with awareness and funding,' says Alisa Wilson, managing director at Accenture. 'We need to stop tackling this piecemeal and instead take a holistic approach across the entire ecosystem—academia, biotech, pharma, providers, and investors.' Wilson stresses that funding isn't just about early-stage startups: It's the fuel that powers the entire pipeline from preclinical research through commercialization. Zheng agrees. 'You need funding at every step—academic research, company formation, clinical validation, and market access. If the capital doesn't flow at each of those stages, innovation stalls.' At the root of the underinvestment problem is a lingering misconception that women's health is synonymous with reproductive health. While areas like fertility, contraception, and menopause have received more attention in recent years, conditions that affect women differently or disproportionately—such as autoimmune disease, cardiovascular disease, and cognitive decline—are even more underfunded and under-researched. A study found that women make up 78% of autoimmune disease patients, yet most immunology research still centers on male biology. In cardiovascular research, women account for just 38% of participants in clinical trials, even though heart disease is the leading cause of death for women globally, more than all cancers combined. 'There's still this assumption that we can just extrapolate from male data,' says Wilson. 'But women have 51% more adverse events across all products, likely because dosing, efficacy, and safety haven't been adequately studied by sex. That's a business problem as much as a health one.' The irony is that addressing the women's health gap isn't just a social imperative—it's a massive economic opportunity. A McKinsey report estimated that closing the women's health gap could add $1 trillion to the global economy by 2040 through increased productivity, reduced healthcare costs, and better health outcomes. 'This is a long game,' says Wilson. 'Better data and earlier intervention can improve therapy adherence, reduce hospitalizations, and ultimately lower costs. For pharma, that means more patients staying on treatment longer. For insurers, it's fewer high-cost emergencies. Everyone wins.' The private market is starting to take notice. At Springboard Enterprises, which accelerates the success of women-led health companies, menopause has become one of the fastest-growing areas of deal flow. Investment in women's health-specific conditions tripled between 2019 and 2024. Funding for health conditions adjacent to women's health grew even more. 'We're also seeing interest grow in cardiovascular and autoimmune conditions, as investors recognize how deeply women are affected,' says Miranda Ewald, director of programs at Springboard. Yet significant white space remains. Zheng highlights cognitive health and postmenopausal aging as two critical areas where funding is urgently needed. 'There's an entire spectrum of women's health issues tied to hormonal changes—brain health, bone density, cardiovascular risks—but they've been largely ignored by research and investment communities.' Even when founders tackle these high-need areas, they face challenges in positioning their companies effectively. For years, women's health startups had to shoehorn their solutions into the narrow definitions of femtech or reproductive care to get investor attention. That's changing. 'We're starting to see a shift away from fertility as the dominant narrative,' says Ewald. 'In fact, many investors are now more interested in startups that have broader applications, like bone health technologies that started with women but can scale to serve all populations.' Still, the term 'women's health' itself remains a double-edged sword. 'Ironically, some generalist investors told us they're more likely to invest if a company doesn't brand itself as a women's health company—even if it clearly is,' says Zheng. 'That's how deep the bias runs.' Accenture and Springboard's framework aims to broaden the scope. Instead of viewing women's health as a niche, the report categorizes conditions into three buckets: those that are exclusive to women, differently experienced by women, and disproportionately affect women. That includes everything from endometriosis and menopause to heart disease and Alzheimer's. Accelerating innovation in women's health unlocks economic and health gains that benefit everyone—not just women. This broader lens reframes women's health as a systemic public health issue—one that affects not only women but also their families, workplaces, and economies. 'We need to stop asking why women's health matters,' says Wilson. 'The better question is, how much longer can we afford to ignore it?' It's time for funders—public, private, and philanthropic—to realign their priorities. The evidence is clear: women's health is not just about reproduction, and it's not just a women's issue. It's a societal one. Closing the funding gap could unlock better care, stronger economies, and longer, healthier lives for everyone. If we redefine women's health, we can shape a better healthier future for everyone.
New York Times
5 hours ago
- New York Times
Should We Test Babies for Incurable Diseases?
In every postpartum hospital unit across the country, 1-day-old babies undergo the same ritual: A nurse pricks the newborn's heel and stamps tiny drops of blood onto a paper filter, which is then sent off for a standard screening panel. Today, that panel checks for unusual bio-markers that may indicate a rare but treatable disease like sickle cell anemia or cystic fibrosis. But what if that same dried blood spot could tell you about the baby's risk of developing certain conditions later in life — some with no method of prevention or cure? What if that heel prick could tell you that the baby was almost certainly going to be diagnosed with autism by the time they turned 5? Or that the child would be more likely to develop breast cancer as an adult? Would you want to know? Would she? These questions are no longer hypothetical. Tens of thousands of parents have sought such insights by enrolling their newborns in research projects that examine the baby's genome — the full blueprint for her growing body. As the cost of sequencing plummets, the practice of analyzing hundreds of genes in healthy babies is quietly on the rise, ushering in new questions about where to draw the boundaries of knowledge — and who should get to decide. Scientifically speaking, the possibilities are almost endless. Since virtually every disease has some basis in our genes, the full genome — with three billion base pairs, coding some 20,000 genes — contains a wealth of data to be mined for lifesaving intel and gut-wrenching secrets. But the experts are divided. Some say that revealing a risk of an incurable illness will only put parents in distress, bombarding them with despairing predictions for their young child's life. Others believe any data about diseases that arise in adulthood, like breast or colon cancer, must be excluded, since they violate that future adult's privacy and autonomy — in other words, the right not to know. Want all of The Times? Subscribe.
